Search

2024 AUG 29 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on gynecologic cancer have been published. According to news reporting out [...]

2024 AUG 29 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on brain metastasis have been presented. According to news reporting out of [...]

2024 AUG 15 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A third of cancer patients face chronic pain - a debilitating condition that can [...]

2024 AUG 1 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on cervical cancer is the subject of a new report. According to [...]

2024 AUG 1 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]

2024 JUL 18 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Researchers detail new data in breast cancer. According to news reporting originating from Tehran, [...]

2024 JUL 4 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Horner syndrome. According to news reporting from Beijing, People's [...]

2024 JUL 4 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on hereditary nonpolyposis colorectal cancer have been published. According to news [...]

2024 JUL 4 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators discuss new findings in breast cancer. According to news reporting originating from Puducherry, [...]

2024 JUN 20 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Researchers detail new data in hereditary nonpolyposis colorectal cancer. According to news originating from [...]

2024 JUN 13 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on gynecologic cancer is the subject of a new report. According to [...]

2024 MAY 9 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]

2024 APR 18 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following [...]

2024 APR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on cancer have been published. According to news reporting out of [...]

2024 APR 4 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Milan, Italy: A team of international researchers have developed an artificial intelligence (AI) tool [...]

2024 MAR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on rectal cancer. According to news originating from Sion, Switzerland, [...]

2024 MAR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on breast cancer is now available. According to news reporting from [...]

2024 MAR 7 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Oncology - Gynecologic Cancer have been published. According to news [...]

2024 FEB 15 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A common test used to decide whether breast cancer patients should get chemotherapy may [...]

2024 JAN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Researchers detail new data in cervical cancer. According to news reporting originating from Bihar, [...]

2024 JAN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators discuss new findings in breast cancer. According to news reporting originating from Toronto, [...]

2024 JAN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following [...]

2024 JAN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on Oncology - Cervical Cancer is the subject of a report. According [...]

2023 DEC 28 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Oncology - Breast Cancer have been published. According to news [...]

2023 DEC 28 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following [...]

2023 NOV 30 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Researchers detail new data in breast cancer. According to news originating from the Motamed [...]

2023 NOV 23 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on breast cancer screening have been published. According to news reporting [...]

2023 NOV 23 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following [...]

2023 NOV 16 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on ovarian cancer. According to news reporting out of Kashihara, [...]

2023 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused on [...]

2023 OCT 19 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- LOS ANGELES - City of Hope, one of the largest cancer research and treatment [...]

2023 OCT 5 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on ovarian cancer is now available. According to news originating from [...]

2023 SEP 28 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following [...]

A computational tool has been developed to predict treatment outcomes in cells from High-Grade Serous Ovarian Cancer patients. The tool aims to improve treatment effectiveness by selecting the most suitable drugs for each patient, addressing issues such as late-stage diagnosis and therapy resistance. The simulator has been validated on cell lines and patient-derived models, offering potential for personalized medicine and disease monitoring in ovarian cancer research. This preprint article highlights the importance of such tools in advancing understanding of cancer behavior and treatment selection. [Extracted from the article]

The patent application titled "Methods And Compositions For Treating Cancer" discusses the development of a bispecific antibody targeting PD-1 and LAG3 for the treatment of various cancers, including melanoma and liver cancer. The method involves administering the bispecific antibody at a fixed dose of 600 mg every three weeks. The application highlights the urgent need for novel therapeutic approaches in cancer treatment due to the increasing incidence and significant global public health impact of cancers like melanoma and liver cancer. [Extracted from the article]

A recent study from the University of Pittsburgh explores the relationship between unhealthy visceral fat and the efficacy of immunotherapy in treating endometrial cancer. Surprisingly, patients with higher levels of visceral adipose tissue, typically considered unhealthy, showed improved treatment outcomes. The research suggests that visceral adiposity could serve as a biomarker for personalized treatment strategies and highlights the potential for future therapeutic interventions targeting adipose-derived mediators. [Extracted from the article]

Oncoinvent has initiated a Phase 2 clinical trial of Radspherin in ovarian cancer patients with peritoneal carcinomatosis. Radspherin is an alpha-radiation therapy designed for targeted treatment of cancers that have spread to body cavities. The trial aims to assess progression-free survival in patients following complete surgical resection and pre-operative chemotherapy, with positive Phase 1/2a data showing promising safety and efficacy. This development marks a significant step in Oncoinvent's mission to improve outcomes for patients with peritoneal carcinomatosis. [Extracted from the article]

Researchers from Tehran University of Medical Sciences conducted a study to predict immunohistochemical biomarkers in breast cancer using radiomic features from F-18-FDG PET/CT images. The study included 62 patients with locally advanced breast cancer, and machine learning classifiers based on PET, CT, and PET/CT radiomic features were found to correlate with the immunohistochemical biomarkers. The research was supported by various institutions and concluded that these predictive models could be valuable in diagnosing breast cancer. The study was published in the Journal of Medical and Biological Engineering and can be accessed online. [Extracted from the article]

The University of Texas MD Anderson Cancer Center has partnered with the Union for International Cancer Control (UICC) to enhance women's cancer care globally, focusing on breast and cervical cancers. This collaboration aims to address the disparities in cancer care and outcomes, particularly in resource-limited regions. Kathleen Schmeler, an experienced global health advocate, has been elected to the UICC Board of Directors to contribute to the organization's mission of reducing the global cancer burden and promoting equity in cancer control efforts. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the molecular changes that occur as precancerous lesions progress to High-Grade Serous Ovarian Cancer (HGSOC). The study used high-plex imaging and spatial transcriptomics to analyze human tissue samples at different stages of HGSOC development. The findings reveal immune modulating mechanisms within precursor epithelium, characterized by chromosomal instability, persistent interferon signaling, and dysregulated innate and adaptive immunity. The study also identifies potential biomarkers and therapeutic targets for HGSOC interception and clarifies the molecular transitions from precancer to cancer. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

Extended Stay America has announced its renewed partnership with the American Cancer Society, designating it as the Official Hotel Partner. Over the next two years, Extended Stay America will provide 100,000 free and discounted room nights per year to cancer patients and their families, totaling over $7 million in value. The company aims to reduce disparities in cancer outcomes by helping patients affordably access necessary treatment. Since 2013, Extended Stay America has already assisted over 8,500 cancer patients and their families, saving them over $15 million in lodging costs. The partnership renewal coincides with Breast Cancer Awareness Month, and Extended Stay America representatives will participate in the American Cancer Society's Making Strides Against Breast Cancer walks. Patients can confirm eligibility for the program by calling the American Cancer Society hotline. [Extracted from the article]

A new study funded by the National Institute for Health and Care Research (NIHR) and led by Professor Sudha Sundar from the University of Birmingham has found that an ultrasound test could detect 96% of ovarian cancers in postmenopausal women. The study compared six diagnostic tests and found that the IOTA ADNEX model, which looks at ultrasound features, had the highest accuracy. The researchers recommend that this ultrasound test replace the current standard of care test in the UK. However, it is important to note that the higher sensitivity of the ultrasound test may also lead to some false positives. [Extracted from the article]

This document summarizes a research study conducted by Imperial College London that aims to improve the treatment of brain metastases from breast cancer. The study focuses on a new radiotherapy approach called Dose Escalated internal PTV (DE-iPTV) and its impact on patients' quality of life, control of brain metastasis, and steroid use. Participants will receive 5 doses of radiotherapy, complete weekly quality of life assessments, and undergo MRI scans at specific intervals. The study also includes biomarker analysis and the use of national cancer data. The study is expected to be completed by December 2026 and is not yet recruiting participants. [Extracted from the article]

A recent study conducted by researchers at Golestan University of Medical Sciences in Gorgan, Iran focused on the response rate to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer based on common molecular receptors. The study included 100 patients with breast cancer who underwent NAC treatment followed by surgery. The researchers found that the rate of complete pathological response to NAC in patients with locally advanced breast cancer was 18%. The study also identified significant statistical differences in various factors, such as family history of breast cancer and receptor status, between patients with and without a complete pathological response. [Extracted from the article]

A recent study conducted by researchers at the All India Institute of Medical Sciences (AIIMS) in Raipur, India, explored the role of textural and radiomic analysis parameters in predicting histopathological factors in breast cancer patients. The study involved 212 primary breast cancer patients who underwent F-18-FDG PET/computed tomography for staging. The researchers found that certain parameters, such as SUVmin, SUVmean, SUVstd, SUVmax, and gray level co-occurrence matrix_Contrast, were significantly associated with ductal carcinoma type, luminal subtypes of the tumor, and the grade of the tumor. However, textural analysis could not predict other factors such as hormonal receptor status and molecular subtypes of the tumor. The study highlights the potential of textural and radiomic analysis in predicting certain histopathological parameters of breast cancer noninvasively. [Extracted from the article]

A recent study conducted by the Cameroon Baptist Convention Health Services highlights the challenges faced in managing cervical cancer patients in low-and-middle income countries (LMICs), using Cameroon as a case study. The research reveals that Cameroon has one of the highest incidence and mortality rates of cervical cancer in Africa, with limited access to healthcare facilities, pathology services, and diagnostic imaging procedures. The study emphasizes the need for improved infrastructure, sustainable funding, and multidisciplinary teams to enhance universal health coverage and promote cancer prevention and control programs. The research concludes that addressing these challenges is crucial to providing timely and adequate care to vulnerable and uninformed patients. [Extracted from the article]

A recent report from the Women's Cancer Research Center in Pittsburgh, Pennsylvania discusses the role of ESR1 fusions in breast cancer. The study found that these fusions, which result in the loss of the estrogen receptor's ligand-binding domain, lead to hyperactivation of ER signaling pathways and contribute to drug resistance. The researchers also observed that the specific fusion partner and the cellular landscape influence the activity of these fusions. The study emphasizes the importance of assessing fusion frequency in the context of clinicopathology. [Extracted from the article]

A recent study conducted at Radboud University Nijmegen Medical Center in the Netherlands explored the potential of Siglec-7 and Siglec-9 as immune checkpoint receptors for the treatment of breast cancer. The researchers found that these receptors are highly expressed in triple negative (TN) breast tumors, but to a lesser extent in estrogen receptor positive (ER+) tumors. They also observed higher expression levels of Siglec-7 and Siglec-9 ligands in TN cell lines compared to ER+ cell lines. The study suggests that targeting Siglec receptors through immunotherapy may be a promising treatment strategy for TN breast cancer patients who do not respond to current therapies. [Extracted from the article]

A recent research study conducted at Skane University Hospital in Lund, Sweden, aimed to evaluate patient recovery after implementing patient blood management (PBM) strategies in ovarian cancer surgery. The study included 354 patients with advanced ovarian cancer undergoing surgery between January 2016 and December 2021. The implementation of PBM strategies, such as restrictive red blood cell transfusion, tranexamic acid, and intravenous iron, resulted in a 31% reduction in the number of patients requiring transfusion. Severe complications remained stable, and the length of hospital stay decreased, indicating that PBM is feasible and does not have major adverse effects on short-term recovery. [Extracted from the article]

A recent study conducted at Cedars Sinai Medical Center in Los Angeles, California, examined the patterns of disease recurrence in patients with advanced ovarian cancer who were receiving poly(ADP-ribose) polymerase inhibitor maintenance therapy. The study found that many patients without evidence of disease at the start of maintenance treatment developed new lesions at first recurrence, with the most common sites of recurrence being the peritoneum, lymph nodes, and liver. The researchers suggest that further investigation is needed to determine if combining local therapies with continuous, systemic, targeted maintenance therapy can improve outcomes for these patients. The study was supported by GlaxoSmithKline and published in Gynecologic Oncology. [Extracted from the article]